$GILD Headlines Two tech stocks with big poten
Post# of 144432
Posted On: 09/14/2014 11:08:56 AM
$GILD Headlines
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
FDA tentatively approves Mylan's HIV combo 1:53 p.m. Sept. 13, 2014 - Seeking Alpha
Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog 5:25 p.m. Sept. 12, 2014 - Zacks.com
Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog 4:50 p.m. Sept. 12, 2014 - Zacks.com
Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog 4:30 p.m. Sept. 12, 2014 - Zacks.com
5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 12, 2014 - Investors Business Daily
Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog 6:35 p.m. Sept. 11, 2014 - Zacks.com
Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog 5:55 p.m. Sept. 11, 2014 - Zacks.com
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog 5:45 p.m. Sept. 11, 2014 - Zacks.com
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog 5:20 p.m. Sept. 11, 2014 - Zacks.com
Seattle Genetics-Genmab Expand Deal for Antibody Platform - Analyst Blog 5:15 p.m. Sept. 11, 2014 - Zacks.com
NPS Pharmaceuticals (NPSP) Shoots Up Ahead of FDA Panel - Analyst Blog 4:54 p.m. Sept. 11, 2014 - Zacks.com
Is This the Right Time to Buy Gilead Sciences (GILD) Stock? - Analyst Blog 4:45 p.m. Sept. 11, 2014 - Zacks.com
Medivation Eyes Blockbuster As Cancer Drug Gets An OK 4:41 p.m. Sept. 11, 2014 - Investors Business Daily
Orexigen's Obesity Drug Contrave Approved by the FDA - Analyst Blog 4:30 p.m. Sept. 11, 2014 - Zacks.com
Uncertainty Prevails For Vertex 3:48 p.m. Sept. 11, 2014 - Seeking Alpha
In A Quiet Week, Affimed Therapeutics IPO Could Garner Investor Interest 3:17 p.m. Sept. 11, 2014 - Seeking Alpha
Gilead Sciences: The Shorts Did Indeed Get Squeezed -- What's Next? 11:45 a.m. Sept. 11, 2014 - Seeking Alpha
Gilead Will Continue To Rise 11:20 a.m. Sept. 11, 2014 - Seeking Alpha
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs 10:02 a.m. Sept. 11, 2014 - TheStreet.com
Short Sellers Remain Vigilant Against Biotechs 9:45 a.m. Sept. 11, 2014 - 247WallSt.com
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale 9:10 a.m. Sept. 12, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher 9:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in September 5:00 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
FDA tentatively approves Mylan's HIV combo 1:53 p.m. Sept. 13, 2014 - Seeking Alpha
Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog 5:25 p.m. Sept. 12, 2014 - Zacks.com
Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog 4:50 p.m. Sept. 12, 2014 - Zacks.com
Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog 4:30 p.m. Sept. 12, 2014 - Zacks.com
5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 12, 2014 - Investors Business Daily
Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog 6:35 p.m. Sept. 11, 2014 - Zacks.com
Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog 5:55 p.m. Sept. 11, 2014 - Zacks.com
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog 5:45 p.m. Sept. 11, 2014 - Zacks.com
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog 5:20 p.m. Sept. 11, 2014 - Zacks.com
Seattle Genetics-Genmab Expand Deal for Antibody Platform - Analyst Blog 5:15 p.m. Sept. 11, 2014 - Zacks.com
NPS Pharmaceuticals (NPSP) Shoots Up Ahead of FDA Panel - Analyst Blog 4:54 p.m. Sept. 11, 2014 - Zacks.com
Is This the Right Time to Buy Gilead Sciences (GILD) Stock? - Analyst Blog 4:45 p.m. Sept. 11, 2014 - Zacks.com
Medivation Eyes Blockbuster As Cancer Drug Gets An OK 4:41 p.m. Sept. 11, 2014 - Investors Business Daily
Orexigen's Obesity Drug Contrave Approved by the FDA - Analyst Blog 4:30 p.m. Sept. 11, 2014 - Zacks.com
Uncertainty Prevails For Vertex 3:48 p.m. Sept. 11, 2014 - Seeking Alpha
In A Quiet Week, Affimed Therapeutics IPO Could Garner Investor Interest 3:17 p.m. Sept. 11, 2014 - Seeking Alpha
Gilead Sciences: The Shorts Did Indeed Get Squeezed -- What's Next? 11:45 a.m. Sept. 11, 2014 - Seeking Alpha
Gilead Will Continue To Rise 11:20 a.m. Sept. 11, 2014 - Seeking Alpha
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs 10:02 a.m. Sept. 11, 2014 - TheStreet.com
Short Sellers Remain Vigilant Against Biotechs 9:45 a.m. Sept. 11, 2014 - 247WallSt.com
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale 9:10 a.m. Sept. 12, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher 9:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in September 5:00 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼